Moray Medical Company Profile

Background

Moray Medical, founded in 2017 and headquartered in Mountain View, California, is a medical technology company dedicated to enhancing the quality of life for individuals suffering from mitral valve regurgitation. The company's mission is to democratize access to transcatheter mitral valve repair (TMVR) therapies by simplifying complex procedures through innovative technology. By leveraging proprietary microfluidic robotics, Moray Medical aims to empower cardiologists to perform mitral valve clip therapies more safely, efficiently, and cost-effectively.

Key Strategic Focus

Moray Medical's strategic focus centers on revolutionizing the delivery of TMVR therapies. The company specializes in developing the Coral™ System, an interventional robotics platform designed to simplify minimally invasive cardiovascular interventions. This system integrates microfluidic technology and an augmented reality (AR) digital user interface to enhance precision and ease of use. By targeting the rapidly growing TMVR market, Moray Medical seeks to address the challenges associated with current mechanical instrumentation, which often require extensive training and limit widespread adoption.

Financials and Funding

As of April 2021, Moray Medical has secured a total of $5.7 million in seed funding. The initial seed round, announced in January 2021, raised $3.3 million and was led by 415 CAPITAL, with participation from prominent medtech entrepreneurs. Subsequently, an additional $2.4 million was raised, bringing the total to $5.7 million. Notable investors include Heal Capital and Dr. Fred St. Goar, inventor of the MitralClip™ system. The capital is intended to advance the development of the Coral™ System and support the company's growth initiatives.

Pipeline Development

Moray Medical's primary product in development is the Coral™ System, which comprises:

Driver Assembly: A reusable, wireless unit approximately the size of a brick, incorporating software to direct the movement of the steerable Clipper™ toolset.

Clipper™ Toolset: A single-use, fluid-driven steerable delivery catheter pre-mounted with a cardiac-valve-therapy edge-to-edge clip implant.

Trident™ Input Device: An interface that, in conjunction with robotic coordination and AR visualization, allows interventionists to position and orient the clip with ease.

The Coral™ System is designed to simplify the percutaneous delivery of valve therapies, enabling interventional cardiologists of varying skill levels to perform procedures more effectively. While specific clinical trial stages and timelines have not been publicly disclosed, the company is actively progressing toward bringing this innovative system to market.

Technological Platform and Innovation

Moray Medical's Coral™ System stands out due to its integration of several proprietary technologies and methodologies:

Microfluidic Robotics: Utilizes fluid-driven mechanisms to achieve precise control over catheter movements, enhancing the dexterity and accuracy of interventions.

Augmented Reality (AR) Interface: Incorporates AR visualization to provide real-time, intuitive guidance during procedures, reducing the cognitive load on physicians.

Submersion™ Interface: A digital user interface that allows interventionists to control the placement of the clip as easily as moving a cursor on a screen, streamlining the procedure and reducing the need for extensive training.

These innovations collectively aim to transform the landscape of TMVR by making procedures more accessible and efficient.

Leadership Team

Moray Medical's leadership comprises seasoned professionals with extensive experience in medical technology and surgical robotics:

Mark Barrish: Co-Founder and Chief Executive Officer. With a background in intellectual property and a history of pioneering surgical robotics technologies, Barrish leads the company's strategic vision and operations.

Phillip Laby: Co-Founder and Chief Operating Officer. An esteemed roboticist, Laby has developed core technologies that are now commonplace in surgical robotics, contributing significantly to the company's technological advancements.

Their combined expertise drives Moray Medical's mission to innovate and simplify cardiovascular interventions.

Leadership Changes

In January 2021, Dr. Azin Parhizgar joined Moray Medical's Board of Directors. Dr. Parhizgar brings a wealth of experience, having previously served as CEO and President at Claret Medical, an embolic protection device company acquired by Boston Scientific. Her expertise is expected to provide valuable insights as Moray Medical advances its technologies.

Competitor Profile

Market Insights and Dynamics

The structural heart market is experiencing rapid growth, particularly in the area of Transcatheter Mitral Valve Repair (TMVR). Mitral regurgitation affects millions globally, yet only a small percentage receive treatment due to the complexity and invasiveness of current procedures. As technologies advance, the demand for minimally invasive solutions is expected to increase significantly.

Competitor Analysis

Key competitors in the TMVR space include:

Abbott Laboratories: Developer of the MitraClip™, a leading device in transcatheter mitral valve repair.

Edwards Lifesciences: Offers the PASCAL system, another transcatheter mitral valve repair device.

Neochord: Provides the Neochord DS1000 system, focusing on minimally invasive mitral valve repair.

These companies have established products in the market, emphasizing the need for innovative solutions like Moray Medical's Coral™ System to address existing challenges and expand treatment accessibility.

Strategic Collaborations and Partnerships

In February 2020, Moray Medical announced a collaboration with the Gore Innovation Center. This partnership aims to enhance the control and accuracy of minimally invasive interventional medical procedures. By leveraging Gore's state-of-the-art prototyping lab and engineering expertise, Moray Medical seeks to accelerate the development and scalability of its technologies.

Operational Insights

Moray Medical's strategic considerations include:

Market Positioning: By simplifying complex TMVR procedures, the company aims to differentiate itself from competitors and capture a significant share of the growing market.

Competitive Advantages: The integration of microfluidic robotics and AR interfaces offers a unique value proposition, potentially reducing procedure times and training requirements.

Scalability: Collaborations with established entities like the Gore Innovation Center provide resources and expertise to scale operations effectively.

Strategic Opportunities and Future Directions

Looking ahead, Moray Medical plans to:

Advance Product Development: Continue refining the Coral™ System to meet regulatory standards and prepare for clinical trials.

Expand Market Reach: Explore opportunities to introduce the Coral™ System to international markets, addressing the global need for accessible TMVR solutions.

Innovate Further: Invest in research and development to expand the application of its technologies to other cardiovascular interventions.

By leveraging its current strengths and strategic partnerships, Moray Medical is well-positioned to achieve these objectives and make a significant impact in the field of interventional cardiology.